ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Molecular regulation by ubiquitin-specific proteases (USPs) in HCC: cell cycle, oncogenic signaling, and beyond.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ubiquitin-specific proteases (USPs) are a large family of deubiquitinating enzymes that all serve the important function of removing ubiquitin moieties from target proteins, thereby maintaining cellular homeostasis. Post-translational modifications, including ubiquitin modifications, play a crucial role in regulating protein stability, localization, and function, thereby profoundly influencing cellular processes such as cell cycle progression, signal transduction, and the response to DNA damage. Increasingly extensive evidence indicates that altered USP activity creates dysfunction of these fundamental cellular pathways and initiates and promotes multiple cancers, including hepatocellular carcinoma (HCC). In HCC, aberrant USP activity directly alters tumor cell proliferation and survival pathways, as well as metastasis, by manipulating oncogenic signaling networks and cellular stress responses. The altered expression or function of multiple USPs has been associated with aggressiveness and poor clinical outcomes, suggesting that USPs may have potential as prognostic biomarkers. Additionally, USPs are ideal therapeutic targets because their enzymatic activity can be selectively inhibited, thereby restoring normal ubiquitination-dependent signaling pathways that are frequently hijacked in cancer. The goal of this review is to provide an overview of current knowledge on the roles of USPs in HCC pathogenesis, with an emphasis on our understanding of their combined effect on major biological processes that underpin or augment tumor development. We highlight our understanding of how USPs regulate oncogenic pathways and cellular behavior in HCC, which forms the basis for this important area of future research aimed at developing novel USP-based therapies. Understanding USP biology in HCC represents a significant opportunity to inform the development of new cancer therapies.
Indexed as
Identifiers
40699238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.